Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serine β-lactamases are a family of bacterial enzymes that hydrolyze β-lactam antibiotics, conferring resistance. They are classified into classes A, C, and D, and utilize a serine residue in their active site for catalysis. The mechanism involves acylation and deacylation steps, leading to antibiotic inactivation. Inhibition strategies involve drugs like clavulanic acid, tazobactam, and avibactam, which form acyl-enzyme complexes or inhibit the enzyme through other mechanisms. They are a major contributor to antibiotic resistance.
Acylation–deacylation using nucleophilic attack by active-site serine. The nucleophilic serine is activated by a general base and attacks the carbonyl carbon, generating an acylenzyme intermediate.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serine β-Lactamase.